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Introduction
Hereditary recurrent fever syndromes (HRFS) can have a
profound impact on health related quality of life (HRQoL)
but there have been relative few prospective studies.
Objectives
To assess HRQoL in patients aged over 17 years with con-
firmed CAPS, TRAPS and MKD and to assess the effect of
treatment with biologic therapies.
Methods
Patients completed the 36-item Short Form Health Survey
(SF-36). Data were collected on untreated patients and
those on long term treatment with biologics. SF-36 mea-
sures the impact of disease on overall quality of life.
Results are expressed as physical-component summary
score (PCS) and a mental-component summary score
(MCS). Scores range from 0 at worst to 100 at best, with
values greater than 50 indicating a better HRQoL than
that of a normal adult in the United States.
Results
In CAPS pre treatment HRQoL scores were available on
18 patients, 11 female, median age 43.6 years (IQ 27.9-
47.1). The most affected domains were bodily pain, mean
score 44, general health 32.5 and vitality 40.3. After treat-
ment with anti IL-1 agents HRQoL was available on 31
patients, 13 female, median age 40.1 years (IQ 27.7:47.8).
There was an improvement of more than 20 across all
domains except role emotional which improved by 11 and
scored above the US average on all domains. There was
no significance difference in HRQoL in the 26 patients on
long term canakinumab and the 8 on anakinra (one
patient provided data on both agents). Data were available
on 7 cases of TRAPS who have never received biologics
(5 females, median age 443yrs (IQ: 24:44)) and 13 prior to
biologics (10 females, median age 39 yrs (IQ 18.5:37)).
HRQoL in patients managed with episodic steroids was
near normal across all domains, mean PCS 49.7, MCS
52.6. In patients whose disease was severe enough to
require biologics pretreatment scores were significantly
lower, mean PCS 38.7 and MCS 43.0. In 19 TRAPS
patients on biologics (13 female, median age 42.6 yrs (IQ
28:50), 3 with AA amyloidosis) HRQoL was significantly
better across all domains, mean PCS 49.1 and MCS 51
than prebiologics but no different to those adequately
managed with steroids. Of 6 patients with MKD (1 female,
median age 28.1 yrs (IQ 24.4:31.8)) all had severe disease
(5 on biologics , 4 refractory to etanercept, 3 refractory to
anakinra, 1 refractory to tocilizumab, 1 with AA amyloido-
sis). Quality of life on no treatment in 2 cases and ineffec-
tive biologics in the others was poor, particularly general
health (mean 22.8) and social function (mean 22.5), mean
PCS 36.1, MCS 28.0. With effective treatment HRQoL
(anakinra 1, canakinumab 1, tocilizumab 2) improved sig-
nificantly across all domains in 4 assessed patients, mean
PCS 48.5, MCS 46.8.
Conclusion
HRQoL improves with effective long term treatment.
Mean scores were worst in untreated MKD. Self reported
improvement was most marked in CAPS c who reported
sustained high scores on anti IL-1 agents. There was also
improvement in patients with TRAPS and MKD and in
treated patients with both diseases HRQoL was almost
the US norm. HRQoL data aids holistic assessment of
disease activity; the improvements reported here mirror
changes in clinical disease activity and inflammatory
markers on treatment and help justify the cost and
potential long-term risks of biologic therapies.
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